Dr. Reddy's Laboratories gets Form 483 with 4 observations from USFDA for Srikakulam formulations facility

The United States Food & Drug Administration (USFDA) completed a product-specific Pre-Approval Inspection (PAI) and a routine GMP inspection at our formulations manufacturing facility in Srikakulam (FTO SEZ PU2). The inspection was conducted from 8th May, 2023 to 12th May, 2023. We have been issued a Form 483 with four observations, which we will address within the stipulated timeline.

Max Healthcare Institute subsidiary updates on land in UP

Crosslay Remedies Limited (CRL), wholly-owned subsidiary of Max Healthcare Institute Limited has entered into an agreement to sell for acquisition of land and building admeasuring 4,000 square meters situated in Uttar Pradesh subject to fulfilment of certain conditions precedents post which CRL shall enter into definitive agreements.